-
There is a greater and greater evidence on the fact that the use of glitazones is associated with an increased risk of fractures and the pathogenetic mechanism is understandable: the receptors for glitazones are present in the bones and there are data indicating that rosiglitazone interferes with [...]
-
Achilles tendinopathy, a more degenerative than inflammatory process, often has its onset after an intense physical activity, so the most used therapies imply rest, anti-inflammatory drugs, manipulations like stretching, even if results are often disappointing and the disorder continues for a long [...]
-
From randomized trials, it results that the use of inhaled steroids does not change bone mineral density, but is the long-term use of these drugs associated with an increased risk of osteoporosis (like in the case of parenteral steroids) or not? In the TORCH trial, performed in 2007, sponsored by [...]
-
Even if the use of bisphosphonates in long-term therapies reduces the incidence of fractures in women with osteoporosis, a strange fracture has been described in some users of these drugs (see image), so the report of these two trials is undoubtedly interesting. In a first report, some orthopedists [...]
-
Denosumab is a monoclonal antibody which decreases bone reabsorption inhibiting a cytokine necessary to the functioning of osteoclasts. For this mechanism of action, this drug, not marketed in the USA yet, has been used for some trials on osteoporosis sponsored by pharmaceutical industry. In one of [...]
-
A prospective trial, called Osteoporotic Fractures in Men, focusing on osteoporosis, has been performed on 6000 US old males (averagely >65). In a starting report, about a quarter of participants presented blood levels of 25(OH)-vitamin D lower than 20 ng/ml. Now, researchers have published the [...]
-
During a bisphosphonate treatment is it necessary to monitor bone mineral density (BMD) referring to the effects of these drugs on bone reabsorption? Some researchers have examined the data from the Fracture Intervention Trial, sponsored by pharmaceutical industry, evaluating the effects of [...]
-
In the GAIT trial, promoted by NIH, performed last year, glucosamine and chondroitin sulfate did not show themselves better than placebo in relieving symptoms of painful knee osteoarthritis or in delaying the progression of the decrease in the joint space. Now, another case-control trial on [...]
-
From performed trials, it results that the new molecules used in the treatment of diabetes (rosiglitazone and pioglitazone) increase the risk of fractures, so a meta-analysis has been performed in order to quantify this risk in a better way. Examining 10 randomized trials, involving about 14,000 [...]
-
There is an association between osteoporotic fractures (above all hip and vertebral fractures) and increased mortality. In order to better quantify this risk, 4005 Australian miners (older than 60 at enrolment) and their families have been followed for 18 years: during this period, there have been [...]